Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Treating hepatitis C: Is sofosbuvir worth it?

Ashish Advani, PharmD
Meds
July 14, 2014
Share
Tweet
Share

In 2011, Food and Drug Administration Commissioner Margaret Hamburg remarked upon a “new direction in the treatment of hepatitis C,” as a success rate of approximately 70% marked a significant improvement over the previous rate of approximately 50%, and suggested a cure was in sight.

Today, that cure has been realized as Sovaldi (sofosbuvir), a novel agent, has shown a success rate of 95% in clinical trials.  Sofosbuvir comes without the debilitating side effects of what was our previous standard of practice, works in less time, eliminates accompanying interferon therapy, and eliminates injections altogether, in favor of a pill that can be taken once daily.  But, most notably (and the primary reason behind the price tag), it represents a virtually unparalleled conquest of a virus without a vaccine, in a population that presents a significant burden upon our health care costs.

Sofosbuvir is the definition of disruptive in a market that craves disruption.  It is on pace to overtake Lipitor (atorvastatin) as the best selling drug of all time, probably within the next three years.  It is well documented that sofosbuvir costs $84,000 for a full 12-week regimen, or $1,000 per pill, and this estimate does not include expenses for diagnostic assays, monitoring, and physician visits.   Importantly, the question we must ask is, “Is it worth it?”

I recently wrote about our spoiled rich kid mentality and opined that instead of the Cadillac, we must learn to choose the Ford, which may very well get us where we need to be just fine.  However, this idea is limited by the cost of disease progression; it makes sense in every situation except disease states in which the consequences of morbidity and mortality associated with treatment failure are costlier than the drug savings.

Hepatitis C seems to fall in this category, which is why it is considered such a valuable industry.   For starters, the cost of a liver transplant is approximately $300,000 per patient, and at least 3 million Americans are infected with hepatitis C (and surely more do not even realize they have it, as it is a “silent disease”).  Despite a recent decrease in new infections, the death toll is increasing as infections incurred years ago have started to take a toll; today, more people die of hepatitis C than human immunodeficiency virus (HIV).  Sofosbuvir makes financial sense mainly because it represents a substantial savings of morbidity and mortality costs associated with progression of hepatitis C.

If the decision were simply between sofosbuvir, a liver transplant, cirrhosis, liver cancer, or death, it would be an easy one.  The decision becomes more complicated when we consider that hepatitis C is unpredictable and it can take decades to damage the liver enough to cause serious liver damage, yet we would pay for the cure today.    An estimated 50% of hepatitis C patients receive some form of government assistance (mainly veterans, prisoners, and those on Medicaid), a population with increasing access to care, based upon the provisions of the Affordable Care Act.   A recent study by the Institute of Clinical and Economic Review (ICER) estimated an additional cost of $18 billion to treat half of California’s Medicaid population.   The CEO of Express Scripts, albeit a biased expert, recently claimed sofosbuvir will “break the country.”

The odds of winning the lottery are approximately 1:176 million, yet data shows that most of us play.  Why?  Because there is a chance of winning.  We must not practice this way in medicine, but we do all too often. Waiting is recommended for many patients — particularly those with little or no liver damage, as competition will inevitably bring the price down.  However, if I were a patient with hepatitis C and I knew of a cure, I would certainly do what I could to get it now.   If we concede that sofosbuvir is worth the price, the most important question then becomes, “Is it worth it for everyone?”

Gilead Sciences, the manufacturer, estimates that only 58,000 Americans are currently undergoing treatment for hepatitis C, and based on their actions to this point, they plan to embark upon the blue ocean strategy of creating a blue ocean by altering the boundaries of an existing red one.  One commonly cited example of this strategy is the success story of Cirque du Soleil, which redefined the circus industry and ultimately created a new form of entertainment, making its competition irrelevant in the process.

It was recently estimated that if Gilead Sciences were able to treat every hepatitis C patient in America, the company would make $227 billion, more than the sale of every other drug combined.  Currently, television advertisements sponsored by Gilead encourage people to get screened and to talk with their doctors about new treatment options.

These are important questions that set a precedent for our future decisions.  These medications are considered the first of a new wave of expensive specialty medications in development, the FDA is bound by law not to consider price when making decisions, drug prices are unregulated, health care is not price elastic, and the days of Jonah Salk altruism are long behind us.  If we are willing to pay $84,000 today to cure for hepatitis C, how much might we pay for a cure for Alzheimer’s Disease?

Ashish Advani is a pharmacist and assistant professor, Mercer University College of Pharmacy, Atlanta, GA.  He is also founder, InpharmD and blogs at Stay InpharmD.

Prev

How doctors can change the way they work and care for patients

July 14, 2014 Kevin 7
…
Next

How to achieve the Triple Aim plus physician satisfaction

July 14, 2014 Kevin 8
…

Tagged as: Gastroenterology

Post navigation

< Previous Post
How doctors can change the way they work and care for patients
Next Post >
How to achieve the Triple Aim plus physician satisfaction

ADVERTISEMENT

More by Ashish Advani, PharmD

  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • a desk with keyboard and ipad with the kevinmd logo

    The United States takes the spoiled rich kid approach to health care

    Ashish Advani, PharmD

More in Meds

  • A psychiatrist’s 20-year journey with ketamine

    Muhamad Aly Rifai, MD
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • Most Popular

  • Past Week

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Could antibiotics beat heart disease where statins failed?

      Larry Kaskel, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Why palliative care is more than just end-of-life support

      Dr. Vishal Parackal | Conditions
    • Why vitamins should be part of the mental health conversation [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why vitamins should be part of the mental health conversation [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • An IMG’s story of exclusion in U.S. residency

      Fereshteh Kagar Bafrani, MD | Physician
    • The 4 foundations that sustain physicians through burnout and balance

      Ananta Subedi, MD, MPH | Physician
    • Should anesthesiologists object to unnecessary procedures?

      Deepak Gupta, MD | Physician
    • Ideology, not evidence, fuels the anti-trans agenda

      Andie Riffer, PhD and Shawn E. Parra, LCSW, MSW | Policy

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 7 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Could antibiotics beat heart disease where statins failed?

      Larry Kaskel, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Why palliative care is more than just end-of-life support

      Dr. Vishal Parackal | Conditions
    • Why vitamins should be part of the mental health conversation [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why vitamins should be part of the mental health conversation [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • An IMG’s story of exclusion in U.S. residency

      Fereshteh Kagar Bafrani, MD | Physician
    • The 4 foundations that sustain physicians through burnout and balance

      Ananta Subedi, MD, MPH | Physician
    • Should anesthesiologists object to unnecessary procedures?

      Deepak Gupta, MD | Physician
    • Ideology, not evidence, fuels the anti-trans agenda

      Andie Riffer, PhD and Shawn E. Parra, LCSW, MSW | Policy

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Treating hepatitis C: Is sofosbuvir worth it?
7 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...